Effects of adding L-arginine orally to standard therapy in patients with COVID-19: A randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis

Effects of adding L-arginine orally to standard therapy in patients with COVID-19: A randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis

By Giuseppe Fiorentino published in The Lancet September 9, 2021 below with analysis of the article & research by Chris Masterjohn, PhD below and commentary by Mark Bricca, ND "Based on an interim analysis recently published in a journal affiliated with...

read more